Search Immortality Topics:

Page 120«..1020..119120121122..130140..»


Category Archives: Genetic Medicine

Analysts Anticipate Wave Life Sciences Ltd (NASDAQ:WVE) Will Announce Earnings of -$1.48 Per Share – Slater Sentinel

Equities analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to report earnings of ($1.48) per share for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Wave Life Sciences earnings, with estimates ranging from ($1.81) to ($1.21). Wave Life Sciences posted earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 14.7%. The business is scheduled to report its next earnings report on Friday, March 6th.

According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($5.54) per share for the current year, with EPS estimates ranging from ($5.87) to ($5.27). For the next year, analysts anticipate that the firm will post earnings of ($3.18) per share, with EPS estimates ranging from ($4.77) to ($1.61). Zacks EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Wave Life Sciences.

A number of equities research analysts recently weighed in on the stock. SunTrust Banks restated a buy rating and set a $20.00 price objective on shares of Wave Life Sciences in a research note on Tuesday, December 31st. Guggenheim cut their price objective on shares of Wave Life Sciences from $43.00 to $25.00 and set a buy rating on the stock in a research note on Tuesday, December 17th. Zacks Investment Research upgraded shares of Wave Life Sciences from a hold rating to a buy rating and set a $9.25 price objective on the stock in a research note on Saturday, January 11th. Leerink Swann cut shares of Wave Life Sciences from an outperform rating to a market perform rating and cut their price objective for the company from $33.00 to $10.00 in a research note on Tuesday, December 31st. Finally, Mizuho assumed coverage on shares of Wave Life Sciences in a research note on Monday, December 30th. They set a buy rating and a $65.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Wave Life Sciences has an average rating of Buy and a consensus target price of $22.75.

A number of institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. acquired a new stake in Wave Life Sciences during the 4th quarter worth about $538,000. Redmile Group LLC grew its stake in Wave Life Sciences by 16.8% during the 3rd quarter. Redmile Group LLC now owns 3,177,760 shares of the companys stock valued at $65,239,000 after acquiring an additional 458,053 shares in the last quarter. Barclays PLC grew its stake in Wave Life Sciences by 39.5% during the 3rd quarter. Barclays PLC now owns 23,459 shares of the companys stock valued at $482,000 after acquiring an additional 6,647 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Wave Life Sciences by 3.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 45,000 shares of the companys stock valued at $924,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Matisse Capital grew its stake in Wave Life Sciences by 9.3% during the 3rd quarter. Matisse Capital now owns 66,486 shares of the companys stock valued at $1,365,000 after acquiring an additional 5,660 shares in the last quarter. Hedge funds and other institutional investors own 90.26% of the companys stock.

Shares of NASDAQ WVE opened at $7.71 on Thursday. Wave Life Sciences has a fifty-two week low of $6.89 and a fifty-two week high of $48.64. The firms 50-day simple moving average is $9.37 and its 200 day simple moving average is $20.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.88 and a current ratio of 1.88.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Recommended Story: Technical Indicators What is a Golden Cross?

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Read the rest here:
Analysts Anticipate Wave Life Sciences Ltd (NASDAQ:WVE) Will Announce Earnings of -$1.48 Per Share - Slater Sentinel

Posted in Genetic Medicine | Comments Off on Analysts Anticipate Wave Life Sciences Ltd (NASDAQ:WVE) Will Announce Earnings of -$1.48 Per Share – Slater Sentinel

Major advances in heart care are reshaping health industry – Sunbury Daily Item

According to local doctors, two areas of advancements have been drastically changing the heart health field: Finding less invasive ways to perform heart procedures and focusing more on genetic therapies.

Probably the biggest thing is TAVR, a way of replacing the aortic valve without having to do open heart surgery, Donald Nardone, MD, cardiologist, UPMC. We do them here.

TAVR (transcatheter aortic valve replacement) is a minimally invasive surgical procedure that repairs the valve by wedging a replacement valve into the aortic valves place, according to the American Heart Associations website.

While not necessarily a new procedure, it is being used for more patients.

Initially it was for people who are very, very high risk for open heart surgery, but studies have been done and it has transitioned into a procedure available for patients in all risk categories, Nardone said.

Benefits include a shorter hospital stay usually in and out in one day and a much quicker recovery. There is a question of durability, Nardone said: It is not yet known how long the valves will last and whether they would be a good option for younger patients.

John Pfeiffer, MD, cardiologist at Heart and Vascular Center of Evangelical, in Lewisburg, talked about leaky mitral valves, which dont close properly, thus allowing some blood to flow backward into the heart. They can sometimes be treated with medication, but for severe cases, a new, tiny mitral clip can repair or replace the valve in a less invasive procedure than traditional open heart surgery.

I think well see more of that in the future, techniques of less invasive options, Pfeiffer said.

Sandy Green, MD, associate interventional cardiology at the Cardiovascular Center for Clinical Research, Geisinger Medical Center, in Danville, agreed.

The name of the future is two-fold, he said. I think were going to be able to do a lot to keep people from having a heart attack or having valve problems or heart failure because of advances in medicine. And were going to be able to fix a lot of those problems without having to do open heart surgery.

Prevention a priority

Newer medications will help patients control cholesterol and other heart issues.

Finding ways to lower the risk of having a heart attack, stroke or other potentially fatal cardiovascular problem is a priority for researchers, Nardone said.

He pointed out the benefit of a new class of medications that includes the PCSK9 inhibitors, a twice-monthly injection that can achieve a 50 percent drop in cholesterol levels.

These drugs affect cholesterol numbers and also reduce the risk of heart disease and stroke, Nardone said.

Theyre good for people who cant take statins or are on a high level of them. Theyre very, very effective, so thats pretty exciting for the treatment of cholesterol.

Pfeiffer mentioned Repatha, a PCSK9 inhibitor that he has prescribed to patients.

Ive seen good results in terms of lowering cholesterol, he said. The problem is, its expensive.

The American Heart association now suggests a more aggressive treatment of high blood pressure, which is probably the number one risk factor for stroke, heart disease or kidney failure.

Treating the blood pressure to a normal level has become more important, Nardone said.

Sorting through statistics

About 5.7 million adults in the United States have heart failure, according to the Center for Disease Control.

Heart failure occurs because the heart doesnt pump well, or because it doesnt relax and fill properly with blood, Nardone said, adding that the drug Entresto helps people who have a bad heart pump.

Today, Nardone said, overall incidences of heart disease have somewhat declined, but he fears that trend may reverse because more young people are smoking and dealing with obesity and diabetes. I hope that we dont see that trend start to reverse itself.

Most cardiac conditions increase with age, Pfeiffer said, noting that as the Baby Boomer generation ages, incidences of heart disease will increase. People used to die of heart attacks in their 60s.

People with heart disease are now living longer and having a better quality of life than they used to.

When we started doing stents, theres no question we saved a lot of lives, Pfeiffer said. Thats the really exciting thing with medicine, I think, where we can say we saved your life with this treatment. Those kinds of things really make you feel great about the medical field.

In general, the incidence of heart disease is still very common, but at least for a while there it was heading in the right direction, Nardone said. And for people who do have heart disease, its not always a terminal diagnosis anymore. The treatment for valve problems, heart failure, coronary disease, thats gotten to the point where theres much more that you can do for people.

I would say the incidences of heart disease are fewer, but maybe as a society we dont take as good care of ourselves as we should.

New problems

Something the average person doesnt have to worry about is dealing with cancer and cardiovascular problems at the same time. But with the advancements in the treatment of cancer with targeted medications, new cardiology problems have arisen.

Targeted medications attack specific molecules inside cancer cells, causing little or no damage to healthy cells.

But all drugs have side effects, and among those of targeted meds are heart problems.

This has led to a new field that Nardone is interested in: cardio oncology, with an emphasis on trying to assess the risk of having heart complications during targeted medication treatment.

Doctors in this field would collaborate with a patients family doctor and oncologist to find ways to prevent or treat heart complications during targeted medication treatment to get them the cancer treatment they need and try to minimize the possibilities of cardiac side effects, Nardone said.

Steps for success

All three doctors emphasized that its better to avoid heart problems than to treat them.

If we take care of ourselves then thats the most important, the best thing, Nardone said.

Weve got to get people off the couch and get out and enjoy the outdoors as much as possible. If I could stress anything, its much better to prevent heart problems than it is to treat them.

No. 1, dont smoke, Pfeiffer said. No. 2 would be regular exercise, and then a healthy, common-sense diet. Keep on top of risk factors like hypertension and diabetes. Make sure you keep those types of things controlled.

He and Green both mentioned the emerging studies of genetic medicines to keep hearts healthy by controlling risk factors like diabetes, high blood pressure and cholesterol.

The two things Im optimistic about are artificial intelligence in medicine, Pfeiffer said, and genetic therapies for conditions that have an underlying genetic basis.

I think were going to be able to regrow heart tissue, as well, Green said. I think thats the future of cardiology. I mean, when that stuff gets here, its going to make the stuff were doing now look like were in the Stone Age.

Read the original post:
Major advances in heart care are reshaping health industry - Sunbury Daily Item

Posted in Genetic Medicine | Comments Off on Major advances in heart care are reshaping health industry – Sunbury Daily Item

If You Invested $100 in CRISPR Therapeutics’ IPO, This Is How Much Money You’d Have Now – Motley Fool

Swiss biotech CRISPR Therapeutics (NASDAQ:CRSP) went public in 2016, using the capital markets to help fund its potentially groundbreaking gene-editing technology. Using the CRISPR/Cas9 process, scientists can add, delete, or replace specific sections of DNA. The potential to correct genetic defects and develop personalized medicine provides a multitude of options for the company to pursue.

The power and promise of CRISPR/Cas9 have swept the scientific community at large. Some speculate that it's only a matter of time until the Nobel Prize in Medicine is awarded to the scientists who unlocked its potential to replace or remove faulty sections of DNA, using a process they observed in our own bacteria(CRISPR stands for "clustered regularly interspaced short palindromic repeats," and Cas9 is the protein that makes it work). Several companies, like CRISPR Therapeutics, emerged to translate this powerful tool into a valuable therapy for humans.

Now, back to the question at hand. How much would a $100 investment into CRISPR Therapeutics be worth today for those investors who participated in the initial public offering (IPO)?

Image Source: Getty Images.

CRISPR Therapeutics priced its IPO at $14 per share. The stock commenced trading at $15 on Oct. 19, 2016, and went as low as $14.01 and as high as $16.32 before closing its first day at $14.09.

An initial $100 investment into CRISPR would yield seven IPO shares (fractional shares excluded). That $100 would be worth $383.88 based on Wednesday's closing price of $54.84. For those savvy (or even just lucky) enough to get some IPO shares, the stock produced an attractive gain of 391%.

That price highlights the demand by investors and the potential power of the company's platform technology to treat diseases. CRISPR Therapeutics also has the advantage of having the most advanced drug candidate in clinical trials. Specifically, the company has a gene therapy product for the treatment of beta thalassemia and sickle cell disease. These genetic blood diseases impair the ability of hemoglobin to carry oxygen throughout the body. This can lead to a lifetime of anemia, blood transfusions, and pain, and even premature death.

2016 was the year for biotech IPOs focused on CRISPR-Cas9 technology. Editas Medicineled off the pack when it started trading on Feb. 3, 2016. Intellia Therapeutics followed with its public market debut on May 6. Finally, CRISPR offered shares to the public on Oct. 19. So which company made the best investment for investors?

CRISPR Therapeutics' 391% return bested Editas and Intellia. Editas gained a respectable 79% from its IPO, while Intellia lost 19% in value. These event-driven stocks can easily jump around in price, particularly in reaction to news on pipeline programs.

Enthusiasm for the field is high. CRISPR Therapeutics' valuation exceeds $3 billion, yet the company has reported data from only two patients. That's correct, two patients. Gene editing and gene therapy possess the ability to potentially cure a myriad of diseases, but we're still in the early stages of development. These companies are both encouraging and risky. Only investors with high tolerance for risk should invest in biotech companies, particularly those with cutting-edge, unproven technologies.

In 2020, CRISPR Therapeutics should continue to update investors on the trial for beta thalassemia and sickle cell disease. Also, the company expects to present data on its anti-cancer therapy, CTX-110. This approach modifies specific immune system components called T cells so they can recognize the cancer. Importantly, the T cells come from healthy donors, undergo editing, and are then given to patients with certain forms of cancer. The method has been tried using a patient's own T cells, but the long-term goal for the field is to produce a therapy from healthy donors.

Stay tuned to the CRISPR field and CRISPR Therapeutics. Volatile stock swings may be in store for biotech investors owning these stocks. However, the ability to edit disease-causing genes has the potential to redefine the treatment paradigm for genetic diseases.

See the article here:
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now - Motley Fool

Posted in Genetic Medicine | Comments Off on If You Invested $100 in CRISPR Therapeutics’ IPO, This Is How Much Money You’d Have Now – Motley Fool

Researchers Pinpoint Genetic Mutations That May Protect Against Alzheimer’s – Being Patient

By Phil Gutis | February 7th, 2020

Scientists in London have identified a type of genetic mutation that appears to protect against late-onset Alzheimers disease.

For their paper, published in the Annals of Human Genetics, the researchers studied DNA samples taken from more than 10,000 people. They identified a class of gene mutationsor variantsthat they said appear to protect a pathway critical for cell survival.

Calling his teams results quite encouraging, study author David Curtis from the University College of London Genetics Institute said that the genetic variations his team identified make Alzheimers disease less likely to develop.

Drugs which have the same effect might also be protective, Curtis said in a news release.

The research built on previous studies in mice and rats, which suggested that inhibiting the mutations could protect against Alzheimers disease. The new paper marks the first time, the scientists said, that the same effect has been demonstrated in genetic samples from people.

Of the DNA samples that were analyzed, half came from individuals with Alzheimers. The other 5,000 samples came from people without any dementia.

In total, the researchers examined all DNA sequence mutations in more than 15,000 genes, including more than one million individual variants, to identify genes in which damaging mutations were more common in people with or without Alzheimers disease.

Heres a natural experiment in people that helps us understand how Alzheimers disease develops, Curtis added. We can see that the impact of having particular variants is a reduced likelihood of developing Alzheimers disease.

The gene mutations reduced the functioning of proteins called tyrosine phosphatases, which are known to impair the activity of a cell signaling pathway known as PI3K/Akt/GSK-3. This pathway is important for cell survival.

Researchers believe the PI3K/Akt/GSK-3 signaling pathway could be a key target for therapeutic drugs and the findings also strengthen evidence that other genes could be linked to either elevated or reduced risk of Alzheimers disease.

Finding DNA variants that modify the risk of Alzheimers disease is useful as it may help us develop drugs which target the same proteins, Curtis said. As our understanding improves, there may be opportunities to intervene with treatments to prevent the disease from progressing.

Late last year, researchers drew international coverage when they announced they had identified a rare gene mutation that seemingly prevented a woman from developing Alzheimers for decades.

Scientists said the research, published in the journal Nature Medicine, presented a tantalizing clue for why some people are resistant to developing Alzheimers.

Like many members of her extended family, the woman, from Medelln, Colombia, carried a gene mutation called presenilin 1. This gene is known to cause early onset Alzheimers. In fact, researchers said family members with the genetic mutation have a 99.9 percent risk of developing Alzheimers as early as their 30s.

However, the woman did not develop Alzheimers until her late 70s. Scientists suspect the disease was held at bay by another extremely rare gene mutation the woman had called APOE3 Christchurchor APOE3chnamed after Christchurch, New Zealand, where it was first identified.

At virtually the same time, another set of researchers identified genetic mutations related to autism that may play a role in the neurodegenerative disease as well.

The study, out of Tel Aviv University, pinpointed thousands of genetic mutations in aging human brains that overlapped with mutations involved in autism and intellectual disability. They also found that many of these mutations occurred in the cell skeleton/transport system, a network of proteins that help organize cells.

Read more:
Researchers Pinpoint Genetic Mutations That May Protect Against Alzheimer's - Being Patient

Posted in Genetic Medicine | Comments Off on Researchers Pinpoint Genetic Mutations That May Protect Against Alzheimer’s – Being Patient

Virus expert and cancer biologist Harry Rubin dies at 93 – UC Berkeley

Harry Rubin in 1989. (UC Berkeley photo by Jane Scherr)

Harry Rubin, a leader in the search to understand how viruses cause cancer research that ultimately led to the discovery of cancer-causing genes called oncogenes died on Sunday, Feb. 2, at the age of 93. Rubin was a professor emeritus of molecular and cell biology at the University of California, Berkeley.

A veterinarian by training, Rubin began investigating in the 1950s how normal cells turn into cancer cells a process called transformation. This was at a time before genes could be cloned and sequenced, and much of his research relied on manipulating cultured cells in a petri dish.

Many labs were beginning to work with tumor viruses as the only tractable way to understand cancerous transformation, and Rubin chose to focus on a virus known since 1911 to cause cancer in chickens: the Rous sarcoma virus (RSV). RSV is an RNA virus, which means that it carries its genetic instructions in the form of RNA, not DNA. The virus tricks cells into reverse transcribing its RNA into DNA and integrating it into its own genome.

At that time, there was really no way of studying the molecular or genetic basis of cancer by studying cancer cells, because the genome of the cell is so enormous, said G. Steven Martin, one of Rubins former postdoctoral fellows and a UC Berkeley professor emeritus of molecular and cell biology. Before the advent of cloning and genetic sequencing, we couldnt look into the cancer cell and find the genes involved in cancer. Since tumor viruses have such small genomes and carry only a few genes, it was clear that studying tumor viruses would provide an entry point into the basic mechanisms of cancer.

Between 1953 and 1958, Rubin worked as a postdoctoral fellow and, later, as a research fellow in the lab of virologist Renato Dulbecco at the California Institute of Technology in Pasadena. In 1955, Rubin showed that every cell in an RSV-induced tumor was capable of releasing the virus, implying that RSV was permanently associated with the host cell and suggesting that it plays a direct and continuing role in perpetuating the cell in its malignant state.

Then, working with Caltech graduate student Howard Temin, Rubin developed a way to measure the amount of infectious virus using cultured fibroblast cells from chicken embryos. This opened the way for quantitative studies of the mechanism by which RSV transforms normal cells into cancerous cells.

Dulbecco and Temin later shared the 1975 Nobel Prize in Physiology or Medicine for their work on tumor-causing viruses.

When Rubin moved to UC Berkeley in 1958 to join the Department of Virology, he continued work on RSV and developed other assays, including one to detect avian leukosis virus in vaccines, such as the measles vaccine, that are produced in chicken cell cultures.

Harry Rubin and his wife Dorothy.

He also showed that one strain of RSV was a replication-defective virus that could transform normal cells into cancer cells, but required a leukosis virus a helper virus to replicate and spread. In other words, the RSV could transform, but not replicate, itself, while the helper virus could replicate, but not transform.

This was one of the very first observations to suggest that the virus might carry information about cell transformation and tumorigenesis that was separate from the information needed for the replication cycle of the virus, Martin said.

Rubins work on RSV earned him a prized Lasker Award in 1964.

The work of Drs. Rubin and Dulbecco proves that cells can carry, for many generations, a foreign nucleic acid, whether RNA or DNA, that is responsible for the malignant properties of these cells, the Lasker Foundation wrote in giving them the award in clinical research.

Rubin also received the 1961 Eli Lilly Award in Bacteriology and Immunology and the 1963 Merck Research Award for his work on RSV and was elected to the National Academy of Sciences in 1978.

In 1970, a viral gene responsible for cancerous transformation, now known as viral src, or v-src, was identified through genetic and biochemical studies on RSV carried out by Martin, who was then in the Rubin lab, Peter Vogt at the University of Washington in Seattle and Peter Duesberg at UC Berkeley. This allowed Harold Varmus and Michael Bishop of UC San Francisco to identify an analogous gene in the cellular genome a gene evidently stolen by the Rous sarcoma virus. Called cellular src, or c-src, it was the first known proto-oncogene, that is, a normal gene that, when mutated, can trigger cancer. Many more proto-oncogenes have been discovered since then. The discovery won Bishop and Varmus the 1979 Nobel Prize in Physiology or Medicine.

The significance of the work on the Rous sarcoma virus is that it led to the work on cellular genes that can cause cancer, Martin said. The idea that, by studying the virus, one could get an insight into the cellular and genetic mechanism of carcinogenesis was, in fact, vindicated.

Although Rubins research set the stage for the discovery of oncogenes, by the early 1970s he had switched his focus from viruses to the biology of transformed cells, looking at the mechanisms of growth control and, in particular, the role of inorganic ions in cellular regulation. In later years, he studied the origin of spontaneous transformation of animal cells in culture, using this system as a model for tumor progression.

Harry Rubin was born in New York City on June 23, 1926, the son of Russian Jewish immigrants. His father ran a grocery store in Manhattan. As a teenager, he worked on farms in upstate New York and at 16 enrolled in the veterinary school at Cornell University. Upon graduation in 1947 with a D.V.M. degree, he went to Mexico to help with an outbreak of hoof-and-mouth disease, then joined the U.S. Public Health Service in Montgomery, Alabama, to work on viral diseases, including rabies and Eastern equine encephalitis. In a 1991 profile in California Monthly magazine, he referred to it as time spent chasing cows and horses in Mexico and Louisiana.

Seeking new challenges, he enrolled at New York University and, a year later, in 1952, convinced Nobel Prize winner Wendell Stanley to let him work in his Virus Laboratory at UC Berkeley. Rubin transferred to Caltech in 1953, returning to join the UC Berkeley faculty in 1958, where he eventually occupied Stanleys old office. He retired as an emeritus professor in 2001.

Rubin is survived by his wife, Dorothy, of Berkeley; three children, Andrew, Janet and Clinton Rubin; six grandchildren; and six great-grandchildren. He and his wife were longtime members of Congregation Beth Israel in Berkeley.

Go here to see the original:
Virus expert and cancer biologist Harry Rubin dies at 93 - UC Berkeley

Posted in Genetic Medicine | Comments Off on Virus expert and cancer biologist Harry Rubin dies at 93 – UC Berkeley

Europe Precision Medicine Market size predicted to reach USD 40487 million by 2025 – WhaTech Technology and Markets News

The report covers the forecast and analysis of the Europe Precision Medicine market. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million).

Facts and Factors Market Research has published a new report titled Europe Precision Medicine Market By Technology (Big Data Analytics, Gene Sequencing, Companion Diagnostics, Bioinformatics, Drug Discovery, and Others), By End-User(Diagnostic Tool Companies, Clinical Labs, Healthcare IT/Big Data Companies, and Pharma & Biotech Companies), and By Application (Oncology, Respiratory, CNS, Immunology, and Others): Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2025.

According to the report, theEurope Precision Medicine market is predicted to be valued at approximately USD 17,132 million in 2018 and is expected to reach a value of around USD 40,487 million by 2025, at a CAGR of around 13.1% between 2019 and 2025.

Precision medicine is the medical prototype that recommends the healthcare customization through therapies, medical decisions, products, and practices personalized to the individual patient healthcare or medical/clinical requirements. In the precision medicine model, diagnostic testing is utilized for choosing apt or alternate medical treatment mode depending on patients genetic make-up or structure as well as cellular analysis.

Tools used in precision medicine comprise analytics, molecular diagnostics, and imaging techniques.

Request Free Sample Copy of Research Report @www.fnfresearch.com/sample/g-data-275

(The sample of this report is readily available on request).

This Free report sample includes:

Furthermore, precision medicine enhances health outcomes, minimizes toxicity, and raises cost-efficiency. It allows the patient to optimize disease management.

Growing requirement of enhancing patient outcome to impel the market growth in Europe

Patient outcomes are likely to be improved through the utility of precision drugs in the European continent. It comprises of medical institutes ready to make genetic testing & analytics tools and investors willing to compensate the drug costs.

Apart from this, drug institutes in Europe are focusing on creating new personalized modes of treatments while companion diagnostics providers are concentrating on gathering data efficiently. Additionally, genetic analytics help in interpreting the outcomes of the clinical data of the patients.

Moreover, Europe has played a major role in steering the transformation of the healthcare industry through the effective delivery of patient care services. Apparently, growing occurrence of cancer will enhance the demand for the product in Europe over the forecast period.

However, high initial costs of the precision drugs can hamper the market growth during the period from 2019 to 2025. Nevertheless, introduction of new techniques in precision medicine production will offer new growth avenues for the European market, thereby nullifying the negative impact of the hindrances on the market growth over the forecast period.

@www.fnfresearch.com/inquiryg-data-275

Big data analytics segment to register the highest CAGR over the forecast period

The big data analytics segment is set to record the highest growth rate of over 14% during the forecast timeline. The growth of the segment over the forecast timeline is due to constant learning arrangement and real-time knowledge outcomes.

Oncology segment to dominate the application landscape by 2025

The segmental growth over the period from 2019 to 2025 is owing to the launching of new initiatives in the region like the commitment made by the European society for medical oncology in order to aid and shape the emergence of pattern shifting in treating cancer.

Germany to lead the European precision medicine industry growth by 2025

The growth of the market in Germany is owing to large-scale deployments of precision medicine units along with myriad types of services offered by the healthcare firms in the country.

Request customized copy of report @Request customized copy of report @www.fnfresearch.com/customig-data-275

(We customize your report according to your research need. Ask our sales team for report customization)

Some of the key players involved in the business include Thermo Fisher Scientific, Cepheid, Intel Corporation, Randox Laboratories, Novartis, Almac Group, Illumina, Johnson & Johnson, Qiagen, GE Healthcare, Roche, IBM, Laboratory Corporation of America Holdings, Abbott Laboratories, Biomrieux Sa, and Healthcore among others.

This report segments the Europe Precision Medicine market as follows:

Europe Precision Medicine Market: By Technology Analysis

Europe Precision Medicine Market: By End-User Analysis

Europe Precision Medicine Market: By Application Analysis

Europe Precision Medicine Market: By Country-wise Segment Analysis

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
Europe Precision Medicine Market size predicted to reach USD 40487 million by 2025 - WhaTech Technology and Markets News

Posted in Genetic Medicine | Comments Off on Europe Precision Medicine Market size predicted to reach USD 40487 million by 2025 – WhaTech Technology and Markets News